^
Association details:
| Biomarker: | HR negative |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Published date:
10/07/2021
Excerpt:
Recommendations...First line treatment...If ChT is contraindicated in patients with HER2-positive, HR-negative BC, HER2-targeted therapy without ChT (e.g. trastuzumab or trastuzumab/pertuzumab) may be used
DOI:
https://doi.org/10.1016/j.annonc.2021.09.019.
Source:
Title:
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
Published date:
02/10/2022
Excerpt:
The phase III KAITLIN study (NCT01966471) included adults with excised HER2-positive EBC (node-positive or node-negative, hormone receptor-negative, and tumor > 2.0 cm).....Trastuzumab plus pertuzumab plus chemotherapy remains the standard of care for high-risk HER2-positive EBC.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.21.00896
Trial ID:
Source:
Title:
Dual anti-HER2 Therapy with Pertuzumab and Trastuzumab versus Trastuzumab Alone in Addition to Anthracycline and Taxane-Based Neoadjuvant Therapy in Patients with HER2-Positive Early-Stage Breast Cancer; Real-World Data
Published date:
12/02/2023
Excerpt:
The study comprised 528 patients with a median follow-up of 36 months...Dual anti-HER2 therapy (trastuzumab and pertuzumab) was used in 316 (59.8%) patients...Among the whole group, 225 (43.4%) achieved pCR; significantly higher (n=80, 53.7%) in HR-negative compared to 38.3% among those with HR positive disease, p=0.002...Additionally, pCR was higher in patients who received dual antiHER2 (46.2%)...Estimated 3-year DFS was 86.1% with dual anti-HER2...
Source:
Title:
The Add-On Effect of Fluorouracil, Epirubicin, and Cyclophosphamide Regimens for Neoadjuvant Chemotherapy in Human Epidermal Receptor 2 (HER2)-Positive Breast Cancer: A Single-Center Retrospective Study
Published date:
11/04/2023
Excerpt:
In this retrospective, observational study, participants received pertuzumab combination therapy as NAC for HER2-positive primary breast cancer....The pCR rate was 35.3% (12/34 patients). The pCR group had a significantly higher percentage of histopathologic grade III (1/11 patients, p=0.030) and a significantly higher percentage of hormone receptor-negative patients (7/12 patients, p=0.015) than the non-pCR group....Moreover, our results support that the pCR rate is high in patients with hormone receptor-negative, HER2-positive breast cancer.
Secondary therapy:
FEC
DOI:
10.7759/cureus.48255
Source:
Title:
Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer
Published date:
10/07/2022
Excerpt:
Clinical data from patients with HER2-positive breast cancer who received HP combined with chemotherapy as neoadjuvant therapy at 2 institutions from March 2019 to February 2022 were retrospectively analyzed….The overall tpCR rate was 64.9%, and those of TcbHP, THP, and AC-THP were 73.1%, 52.1%, and 65.1%, respectively....The TcbHP regimen had the highest pCR. HR-negative tumors demonstrated a higher pCR.
Secondary therapy:
carboplatin
DOI:
10.1097/MD.0000000000030892
Source:
Title:
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Published date:
04/08/2022
Excerpt:
Pathological complete response was associated with improved invasive disease-free survival (HR 0·14, 95% CI 0·03–0·64; p=0·011)….The WSG-ADAPT-HER2+/HR– trial showed good survival rates in patients with a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel.
DOI:
https://doi.org/10.1016/S1470-2045(22)00159-0
Trial ID:
Source:
Title:
Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
Published date:
03/04/2022
Excerpt:
IHC assessment revealed 40 (70.18%) patients with IHC 3+ and 17 (29.82%) with IHC 2+. 41/57 (71.93%) patients achieved pCR....The response to dual-targeted neoadjuvant therapy with trastuzumab and pertuzumab was adequate in hormone receptor-negative, HER-2-positive breast cancer patients.
DOI:
10.3389/fonc.2022.819818
Source:
Title:
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
Published date:
11/05/2021
Excerpt:
Both T-DM1/P and THP arms ‘graduate’ in all subtypes: predicted pCR rates are 63%, 72% and 33% for T-DM1/P (n = 52), THP (n = 45) and TH (n = 31) respectively. Amongst all HER2+ patients in the TDM-1/P and TH arms, T-DM1/P had a higher estimated pCR rate (55%; 95% PI 41–69%) than TH (25%; 95% PI 11–38%), corresponding to a 99.9% probability that T-DM1/P was superior to TH...In summary, both T-DM1/P and THP significantly increased estimated pCR rates over TH in HER2+ patients, within both HR+ and HR– groups.
Secondary therapy:
paclitaxel
DOI:
https://doi.org/10.1038/s41467-021-26019-y
Source:
Title:
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)
Published date:
09/02/2020
Excerpt:
Multicenter, retrospective study in patients with HER2-positive early BC receiving neoadjuvant treatment with pertuzumab and trastuzumab in routine clinical practice...A total of 243 evaluable patients were included. Pertuzumab and trastuzumab were combined with anthracyclines and taxanes in 74.1% of patients,...The pCR benefit is higher in HR-negative tumors.
DOI:
10.1007/s10549-020-05866-1
